Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated January 13, 2022, reports on share repurchase activities for the period from December 1, 2021, to December 31, 2021. The report is submitted pursuant to Rule 13a-16 of the Securities Exchange Act of 1934 and complies with Article 24-6 of the Financial Instruments and Exchange Act of Japan.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Repurchase Program Authorization: Approved by the Board of Directors on October 28, 2021, for a maximum of 35,000,000 shares with a total budget of JPY 100,000,000,000.
- Program Period: November 2, 2021, to April 29, 2022.
- Repurchases in Reporting Month: No shares were repurchased during December 2021.
- Cumulative Repurchases (as of Dec 31, 2021): 15,335,700 shares for a total amount of JPY 49,979,942,100.
- Program Progress: 43.82% of authorized shares and 49.98% of authorized funds utilized.
- Treasury Shares Disposed: 76 shares were disposed of on December 16, 2021, for JPY 236,512 (related to fractional share requests).
- Treasury Shares Held (as of Dec 31, 2021): 15,511,263 shares out of 1,582,252,525 total issued shares.
Material Changes
The filing does not report material changes to financial performance or operations. The primary update is the status of the ongoing share repurchase program, which remained inactive in terms of new purchases during the December reporting month, though the cumulative total reflects activity from the prior month.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of share repurchase status.
Key Facts for Investor Verification
- Verify the total number of treasury shares held (15,511,263) against the company's latest balance sheet to confirm capital structure.
- Confirm the remaining budget and share count available for repurchase under the October 2021 Board resolution (approx. 19.66 million shares and JPY 50 billion remaining).
- Note that the reported treasury share count excludes shares held by the ESOP trust account and the BIP trust account.
- Check subsequent filings for repurchase activity in January 2022, as the program remains active until April 29, 2022.